Garbag-Chenon A, Fontaine J L, Lasfargues G, Clark H F, Guyot J, Le Moing G, Hessel L, Bricout F
Hôpital Trousseau, Paris, France.
Res Virol. 1989 May-Jun;140(3):207-17. doi: 10.1016/s0923-2516(89)80098-6.
Rotavirus is a major cause of acute gastroenteritis in infants worldwide and there is need for an effective vaccine. Rotavirus Wistar calf 3 (WC3) is a strain of bovine origin attenuated by 12 passages in cell culture. A lyophilized candidate vaccine containing 1 x 10(7) PFU of WC3 has been developed. An oral dose was given to 25 French infants 5-12-months old (mean age 8.6 months). No diarrhoea was observed within 2 weeks after vaccination. Unexplained vomiting was reported once and isolated fever greater than 37.8 degrees C was reported 3 times during the first week. One month later, a neutralizing antibody response to serotypes tested was shown in 88% of cases, with heterotypic responses to human serotype 3 (SA11 strain) in 72% and to type 1 (WA strain) in 48%. The percentage of immune response was similar whether the infant had antibody prior to immunization or not, but a booster effect was observed in children who had pre-immunization rotavirus antibodies. Considering these promising results, efficacy trials are in the planning in different parts of the world.
轮状病毒是全球婴幼儿急性胃肠炎的主要病因，因此需要一种有效的疫苗。轮状病毒Wistar小牛3型（WC3）是一种牛源毒株，经细胞培养传代12次后减毒。已研发出一种冻干候选疫苗，每剂含1×10⁷ PFU的WC3。给25名5至12个月大（平均年龄8.6个月）的法国婴儿口服该疫苗。接种疫苗后2周内未观察到腹泻情况。在第一周内，有1次不明原因呕吐报告，3次体温高于37.8℃的孤立发热报告。一个月后，88%的病例对检测的血清型出现中和抗体反应，其中72%对人血清型3（SA11毒株）出现异型反应，48%对1型（WA毒株）出现异型反应。无论婴儿在免疫前是否有抗体，免疫反应的百分比相似，但在免疫前有轮状病毒抗体的儿童中观察到了加强效应。鉴于这些有前景的结果，世界各地正在计划进行疗效试验。
